The Abington Memory Center cares for those with any problems with memory or cognition.

Mild memory problems and forgetting can be easily overlooked. We provide diagnosis, treatment, and help for those suffering memory or cognitive losses as they get older. We care for patients with neurodegenerative conditions that present with cognitive problems. Practicing medicine is the foundation of what we do; through clinical trials, we build a future of better treatments.

We specialize in treating patients with:
  • Memory loss
  • Mild Cognitive Impairment
  • Dementia
  • Cognitive dysfunction
  • Alzheimer’s disease
  • Dementia with Lewy Bodies
  • Frontal-Temporal Dementia
Abington Memory Center provides:
  • Assessment, evaluation, and diagnostic workup
  • Caregiver education
  • Medication and behavioral management for problems and distress
  • Treatment recommendations
  • Psychosocial support for caregivers
  • Opportunities to participate in research studies

We understand the importance of daily care for those with memory and cognitive issues. We recommend SarahCare, an adult day health care company dedicated to providing a safe and comfortable environment for seniors. Click here to contact SarahCare.

Dr. Weisman serves as director of ANA’s Clinical Research Center and Memory Center. He has been a leading trialist in Alzheimer’s disease research for more than a decade. He developed novel clinical testing, symptom capture methodologies, and conducted many therapeutic trials at the site level.

He received his B.A. in philosophy from Franklin and Marshall and medical degree from Penn State. After an internship in San Francisco, he completed his residency at Yale where he served as chief resident. He then completed fellowship training with Dr. Thal at UCSD, helping to conduct clinical trials at the Alzheimer’s Disease Cooperative Study, and conducting pathology studies in Alzheimer’s disease and Dementia with Lewy Bodies.

Dr. Weisman’s work focuses on patients, conducting clinical trials, and developing evaluations to better allow for early detection of Mild Cognitive Impairment and Alzheimer’s disease.